

## Favipiravir compared to Arbidol for patient with COVID-19 pneumonia

Bibliography: Chen C, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv preprint<sup>1,2</sup>

Certainty assessment							Summary of findings				
Participants (studies) Follow up	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Overall certainty of evidence	Study event rates (%)		Relative effect (95% CI)	Anticipated absolute effects	
							With Arbidol	With Favipiravir		Risk with Arbidol	Risk difference with Favipiravir

**Clinical recovery (follow up: mean 7 days; assessed with: >72hr recovery of body temp, respiratory rate, O2 saturation, cough relief)**

236 (1 RCT)	serious a,b,c	not serious	not serious	serious <sup>d</sup>	none	⊕⊕○○ LOW	120 participants	116 participants	<b>HR 1.29</b> (0.68 to 2.43) [Clinical recovery]	<b>Moderate</b>	
										500 per 1,000	<b>91 more per 1,000</b> (from 124 fewer to 314 more)
										<b>High</b>	
									700 per 1,000	<b>88 more per 1,000</b> (from 141 fewer to 246 more)	

**Cough relief (follow up: mean 7 days)**

122 (1 RCT)	serious a,b,c	not serious	not serious	not serious	none	⊕⊕⊕○ MODERATE	65 participants	57 participants	<b>HR 2.73</b> (1.75 to 4.27) [Cough relief]	<b>High</b>	
										700 per 1,000	<b>263 more per 1,000</b> (from 178 more to 294 more)

**Pyrexia relief (follow up: mean 7 days)**

145 (1 RCT)	serious a,b,c	not serious	not serious	not serious	none	⊕⊕⊕○ MODERATE	74 participants	71 participants	<b>HR 2.42</b> (1.55 to 3.77) [Pyrexia relief]	<b>High</b>	
										700 per 1,000	<b>246 more per 1,000</b> (from 145 more to 289 more)

## Adverse event (follow up: mean 7 days)

236 (1 RCT)	serious a,b,c	not serious	not serious	serious <sup>e</sup>	none	⊕⊕○○ LOW	3/120 (2.5%)	16/116 (13.8%)	<b>RR 1.19</b> (0.95 to 1.45)	25 per 1,000	<b>5 more per 1,000</b> (from 1 fewer to 11 more)
----------------	------------------	-------------	-------------	----------------------	------	-------------	-----------------	-------------------	----------------------------------	-----------------	----------------------------------------------------------------

**CI:** Confidence interval; **HR:** Hazard Ratio; **RR:** Risk ratio

### Explanations

- a. Bias due to deviations from intended interventions (Cochrane RoB 2.0): High
- b. Bias arising from the randomization process (Cochrane RoB 2.0): Some concern
- c. No reason for missing cases (withdrew consent)
- d. 95%CI includes both no effect and appreciable important benefit
- e. 95%CI includes both no effect and harm (may not be exceeding MID)

### References

1. Chen C, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv preprint, <https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v4>; 2020.
2. Chen, . .